Pleasure to be here with you today to provide an update on our Q3 and year-end results. Just would like to say that from January 1st of this year, Oasmia will change the use of the calendar year at its financial year. To make this happen, this presentation does include an abbreviated financial year covering the period from May 1st until December 31st of 2020. That means eight months. The comparative figures for the previous year report the same period of last year, which means 2019. I think it's important for you to understand that. All right. Moving to slide two. This is the forward-looking statement. On slide three, as you heard, today I will be joined by Robert. Robert is our acting CFO, but also our Finance Manager. I would like to move to slide four. 2020 has really been a year of delivery and transformation. Since I joined the company in March last year, we have already made significant progress on delivering on our objectives. We have a clearly defined growth strategy, which I will talk to you a little bit in more details. That is summing up in four pillars. We are maximizing the potential of Apealea together with our partner, Elevar, in the U.S. We are building our pipeline through our in-licensing activities and our own research and development activities as well. We are focusing our resources to make sure that we are investing in the technologies and products or compounds that will bring future success from a commercial standpoint. Finally, we've been building a new leadership team to deliver on this strategy. The goal remains the same. The goal is to build a sustainable, profitable specialty pharma company through in-house R&D, M&A, and licensing in of late-stage assets. On slide five, referring to these four pillars. We have took us some time to put in place this four-pillar strategy for growth. Obviously, we are measuring our progress against each of our objectives over the last eight months. First, the execution on Apealea on our global partnership with Elevar. Clearly, the U.S. regulatory pathway proposed by Elevar has been disclosed end of last year. Elevar has announced a number of commercialization deals signed for Europe, Inceptua, for Middle East and Africa with Taiba. We have also announced a global named patient program with Tanner, and further planned commercial partnership in Asia and Latin America will be announced by Elevar. The pillar two, which is our technology platform. Clearly, there is significant work underway to potentially enhance XR-17. We have also started to work, and I will come back to that, on the next technology platform. Clearly, we have been increasing our focus on partnering in order to leverage proven R&D and regulatory skills. The pillar three, the clinical development of docetaxel micellar, that is ready to enter into phase I-B, perfectly on target and on time, as communicated earlier. This is an agreement that has been developed with the Swiss cancer research firm, SAKK, addressing a large market opportunity in prostate cancer. Pillar four, very important pillar. Clearly, we've been having extensive discussions to acquire promising oncology assets. We've been also working with boutique investment firm to drive the process of out-licensing our animal health assets and also our XR-17 platform. I will continue during the next few months to refer to this four-pillar strategy in order for you to basically evaluate our progress against those objectives. Slide six refers to the financial statements, I will give the floor to Robert for that slide. Thank you, François. I'd like to repeat what François said. Please note that from January 1st, 2021, Oasmia has changed to use the calendar year as its financial year. Therefore, this presentation includes an abbreviated financial year covering the period May 1st to December 31st, 2020. That is eight months. The comparative figures for the previous year are the same period in 2019, May to December. Cash and cash equivalent and short-term investments are SEK 287 million, compared with SEK 326 million. The net cash flow for the year, minus SEK 154 million. Includes one-off costs relating to the restructuring and staff redundancies. The cash burn will continue to be reduced over the year, targeting approximately SEK 12 million per month, a reduction with approximately SEK 100 million per year. The operating cost for the period amounted to minus SEK 131 million, compared with minus SEK 117 for the same period 2019. This was mainly due to one-off staff severance costs from the staff reductions implemented in the first quarter of the year. First two quarters of the year, I should say. Total employee benefits expenses were minus SEK 45 million, compared with minus SEK 39 million. Towards the end of the last financial year, 2019, the capitalization of development costs for Apealea, Paclical, was halted, and amortization for this project started. This has contributed to a significant increase in depreciation for the year. Oasmia has incurred additional restructuring costs during the period. These related primarily to production equipment and previously capitalized leasehold improvements, which were written down in an amount of SEK 5.7 million. Capitalized right of use assets in properties were also written down with SEK 4.1 million, which also contributed to the increase in depreciation and amortization impairment. Total depreciation and amortization impairment costs were minus SEK 28 million, compared with minus SEK 8 million. As part of alignment with the partnership agreement contracted between Oasmia and Elevar in March 2020, commercial production of Apealea was closed in the autumn as Elevar took control of this. In addition, the staff reductions have enabled Oasmia to lease smaller premises for its operation. Accordingly, notice have been given on the current premises, and Oasmia will be moving its operation to these new premises within the next few months. The laboratory operations will remain in Uppsala. That was all from me. Thank you. I'll hereby leave the word back to François. Thank you, Robert. Let's now move on slide seven. This slide shows the commercial rollout of Apealea by Elevar that has been indeed progressing quite well during the past few months. As you know, Elevar has signed a commercial partnership agreement in Europe, Middle East, North African region, and discussions with potential partners are progressing well in Asia, Latin America. Even more importantly, Elevar has now articulated a clear pathway to commercialization in the U.S. A named patient program has been launched outside the U.S. to make Apealea available to patients who need it in market where it's not yet commercially available. Although this is not at all a company guidance, I have included into this slide peak sales estimates that is coming from one of our analysts that covers Oasmia to give you an indication of the potential, assuming obviously a full registration and launch in the U.S. Okay, let's move to slide eight now. This is a slide about our portfolio, which is based on our proprietary technologies. As well as Apealea, which is already approved in Europe for adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. We are about to enter into the clinical development stage with a new approach to prostate cancer with docetaxel micellar. As you know as well, we're working also to add new candidates to this pipeline through in-licensing focused on oncology. As you could see from this slide as well, you know that we have an animal health portfolio that we are planning to partner as it is not clearly the focus of our company. Let's move now on slide nine. As we are working at bringing new compounds, new drug through our pipeline, we are also improving and expanding the use of our technologies. We have hired a specialty consulting firm to drive the partnering with XR17. At the same time, we also planning to initiate significant collaborations with academics to better profile XR17. We have started research on XR18, that is potentially the next generation technology, which we hope will have a greater versatility and potential. This could be viewed as an upgrade of XR17 to overcome some of the shortcomings of XR17. We will continue to work with XR19, where we are in a process to establish proof of concept. To demonstrate the ability of a dual encapsulation process, enabling combination therapy to be delivered in one single IV administration. Let's now move on. Slide 10. Coming behind Apealea, we have this docetaxel micellar program in development for the treatment of prostate cancer. If I may remind you that prostate cancer is the leading cause of cancer death in men worldwide. One out of seven will be diagnosed in their lifetime. 1.3 million men are newly diagnosed with prostate cancer every single year. You may know that docetaxel is commercialized worldwide under the brand name of Taxotere. It's actually widely approved for a range of solid malignancies and is actually the standard of care for advanced prostate cancer. With docetaxel micellar, we are using XR-17 to enable an IV administration of a water-insoluble docetaxel without the usual solubility enhancers. As I said previously, we are working with SAKK to initiate this phase I-B trial in H1 of this year. That is perfectly on track. SAKK is certainly a highly experienced partner. They coordinate around 50 clinical trials per year involving essentially new cancer therapies. Slide 11 addresses some of the in-licensing opportunities that we are looking at. We are fundamentally looking at in-licensing oncology products from the preclinical stage up to phase III. We are doing that in a very systematic and independent way as well in order for us to make the best possible choices. We're also looking at products that are poorly soluble in water that may benefit from our XR-17 technology. To that end, as I mentioned earlier in this conversation, we will pursue external collaboration to address this. Let's now turn to slide 12. We have a process in place underway looking at partnering our animal health assets. That includes two oncology products, Paccal Vet, that is a new XR-17-based formulation of paclitaxel intended for use in dogs. Doxophos Vet, also a new formulation of doxorubicin in combination with XR-17, again, intended for use in dogs for the treatment of lymphoma, which is one of the most common cancers in dogs. I want to remind the audience that having completed the strategic review, we've been able to identify those cost savings that Robert mentioned earlier and synergies as well. The annualized cost savings are around SEK 100 million per year, and that's been delivered. We've been able to reduce the cash burn rate. That is now between SEK 10 million and SEK 12 million per month. The number of employees has been reduced significantly. We have right-sized the company in order to best move the company forward to its next step. We have now a total count that is less than 30 people. Therefore, we believe we have a lean, focused, and agile structure. On top of it, we have decided to move the small staff headquarter that will be moved to Stockholm while we will keep our laboratories in Uppsala. All right, let's move on slide 13. We all know that nothing has been done without a great team, and I'm very pleased to report that we've made very significant strides in this area. The management team is now completed. Peter Selin joined us as a chief business officer by the end of last year. Fredrik Järrsten will be joining us very early March as a CFO, and Dr Heidi Ramstad has actually very recently, a few days ago, joined us as our chief medical officer. Right, looking ahead on slide 14, we have multiple near and midterm catalysts and investment drivers in 2021, as you could see from the slide. We believe that all in all, we have a strong case to invest in Oasmia. We are one of the few companies at a commercial stage, one of the few biotech company that is at a commercial stage with proven capabilities to bring new compounds to the market. We do have a validated technology platform, XR17, with the potential for upgrade and expansion, XR18, for instance. We have a growing oncology pipeline addressing large market potential. This deal with Elevar was certainly transformational for the company, including milestones and revenues. The cash position is strong. That will help us obviously to pursue high-value licensing in and/or M&A opportunities. We are all in all positioned for strong growth. This is where I will end this presentation and take any questions you may have. Thank you for listening. Thank you. If you do wish to ask a question, please press zero one on your telephone keypad. If you wish to withdraw your question, you may do so by pressing zero two to cancel. Our first question comes from the line of Joseph Hedden from Rx Securities. Please go ahead. Good morning. Thanks for taking my questions. It seems that you have had some good success in implementing the cost controls that you announced last year and bringing down the cash burn rate. Now that we are looking at your phase I-B trial of docetaxel micellar starting up, just wondering how the R&D costs might evolve and what kind of an R&D spend you might expect for this year. You mentioned commercial production of Apealea closing in autumn, being transferred to Elevar. Can you confirm that this will be the end of building inventory the way that you have been in the past year or two, and that it will just be production for the Nordics? Is that the right way to think of it? In that case, what kind of a CapEx spend are we looking at to maintain your technology platforms and the production you do have this year? Thanks. I would say, Robert here, that we don't foresee any major increases in the laboratory and development parts. What was your other question there? On the CapEx, am I thinking the right way in terms of the production of Apealea? You've now transferred most of that to Elevar, so you're not going to be building inventory in the same way that you have been. Yeah, that's absolutely correct. Certainly the goal of the lab that remain in Uppsala will be to continue to do research for XR17 and XR18. We will not be engaged in any commercial production for any compound in the near future. That was one of the main reason why we closed down the commercial production facility in Uppsala, basically. I don't think this is our core business. Also this is not part of our mission, which is to become a specialty pharma company, cash profitable. Okay. With that in mind, is there any guidance you could provide on CapEx for this year and maybe going into 2022? Robert? Yeah. No, we cannot disclose that today. Okay. One on docetaxel micellar. Yeah If I may. As the phase I-B starting, I just wondered if you could give us a refresher on what you think the route to market is there. If the phase I-B is successful, is that looking at phase II and then a phase III, or is there a dialogue to be had with regulators about a quicker route, i.e., straight into phase III? First of all, we are in a process to get the final stages to be approved by the SAKK, we will be able, hopefully very soon, to disclose the design of the phase I that hasn't been disclosed yet, provide some further insight about the phase II and phase III. I think the first step is really to disclose the design of the phase I. Clearly the intention will be to develop on our own the phase II if the phase I-B is successful. Okay. Lastly, on XR18, appreciate that there's not a terrible amount that you can say at this stage. Is there anything that you can say about the differentiation from XR17? Is it still micellar technology? It will be, yeah. It is micellar technology. There are a number of shortcomings of XR-17, such as light sensitivity the storage conditions and so on. We are working. We are at the feasibility stage at this point in time, so I don't want to raise reasonable expectations, and I will be able to communicate the progress on that later on. We have initiated that work. Okay. Thank you, François. Thanks, Robert. You're welcome. The next question comes from the line of John Priestner from Edison Investment Research. Please go ahead. Hi, thanks for taking my questions. I have three, so I'll just ask them one at a time for simplicity. Can you provide any additional clarity on the kind of external interest that you've had in the animal health business and really the kind of companies that you've been in contact with? Yes, this is certainly still confidential, so I cannot disclose the name of the companies. There is a great deal of interest out there, absolutely, from mid-size to big size animal health players. That work has started actually very end of last year. Bear with us. We will communicate in due time some progress around that. That's great to hear. Given the XR-17 platform is applicable to a broad range of kind of solubility APIs, can you discuss what the ideal target for M&A specifically would be? Yeah. Two things. First of all, we will be looking at licensing compounds, especially small molecules, that could benefit from the platform. That's not our exclusive intent. The intent is also to beef up the pipeline in oncology in order to get a critical mass. We are pursuing those two ways in parallel. That's great. Elevar's obviously signed the licensing deal for Apealea for Europe and the MENA region. I was wondering if you could just provide any guidance on when you'd expect to start seeing royalties from sales in these territories. Well, that I cannot provide any guidance on royalties. That is kept confidential under the agreement between Elevar and ourselves. You know that Inceptua is the third party supplier for Europe. There will be a transfer of MAH, as we say, manufacturing authorization holder, from us onto Elevar through Inceptua. That's the first step that is currently happening. Inceptua obviously will start the commercialization process of Apealea in Europe. That's great. Thank you very much, François. You're welcome. Just as a final reminder, if you do wish to ask a question, please press zero one on your telephone keypad now. We have one more question from the line of Ted Hagen, who is a private investor. Please go ahead. Good morning. Thank you. What are the main concern from institutional investors, and when do you expect to see them investing in the stock? Also, the same question for board members. Okay. Let me take the question about board members. We are not disclosing anything on the choice of board members to invest or not into the company for reasons you would easily understand. On your first question, I have certainly started a number of first-round discussions with institutions related to Oasmia. That has happened during the last months. Obviously, the focus was on other things such as the strategy, such as the right sizing of the company, implementation of the strategy, hiring the right people. Now I'm focusing my efforts on these institutions. Clearly, the feedback is positive. We are in a good position to be attractive towards these institutions. Some institutions probably are expecting a catalyst to happen with regard to licensing in or an acquisition in order to continue and materialize the dialogue with us. This is what I'm working on. Okay. Thank you very much. Thanks for all the good work. Thank you. As there are no further questions, I'll hand it back for closing remarks. Thank you for listening to this quarterly report. More than ever, I would like to thank the investors for their patience, for their commitment to Oasmia. The turnaround that has been initiated under my leadership close to a year ago is now in its final phase, now we can certainly look to the future in a very favorable way. I would be delighted to report to you any significant news in the very near future as soon as we get them. Thank you again for your attention today, stay in touch.